Drug · DIN 02352311
VOTRIENT
No: cancelled before it was sold
Authorized, then cancelled before it was ever sold in Canada.
Status Cancelled Pre Market since July 8, 2020.
- Drug Identification Number (DIN)
- 02352311
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Pazopanib L01EX03
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PAZOPANIB (PAZOPANIB HYDROCHLORIDE) | 400 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 30, 2015: NOC 17146New Drug Submission (NDS) · Transfer of Drug Identification Number(s)
- May 27, 2010: NOC 11446New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “votrient”. A notice may cover another product or only some lots: read it to see what it covers.
- Votrient: The dissolution is out of specification in the affected lotNovember 16, 2023 · Drugs · Product quality · Type II
Other DINs named VOTRIENT
- DIN 02352303 · Marketed